Cerebrolysin Reconstitution Calculator

No. Cerebrolysin is not FDA-approved, is absent from the WHO Model Essential Medicines List, and appears in no US, EU, or UK dementia guideline,. It is registered and used in roughly 50 countries (chiefly Russia, Eastern Europe, China, and Central Asia) and is recommended for Alzheimer's disease only in Russian clinical practice guidelines,. It is a standardized mixture of low-molecular-weight neuropeptides and free amino acids produced by enzymatic hydrolysis of porcine brain tissue,.

Evidence is split by design. The 2023 Cochrane review (7 RCTs, 1,773 patients) found no reduction in all-cause death (RR 0.96; 95% CI 0.65–1.41) and flagged a possible increase in non-fatal serious adverse events with the 30 mL × 10-day regimen (RR 2.87; 95% CI 1.10–5.23). Newer syntheses lean positive: a 14-RCT meta-analysis (N=2,884) reported greater NIHSS improvement (+1.39 points); an adjunct-to-thrombectomy meta-analysis (N=294, observational) reported functional independence (mRS 0–3) RR 1.56, lower symptomatic hemorrhage (RR 0.12), and 64% lower mortality; and the multinational C-REGS2 study (N=1,769) showed a superior 90-day mRS shift (MW 0.616, p<0.0001). In the randomized CEREHETIS trial, Cerebrolysin added to alteplase cut symptomatic hemorrhagic transformation (OR 0.25; p=0.019) and improved day-14 NIHSS but not day-90 mRS. In the ESCAS RCT, aphasia (WAB) scores improved 14.8 points over placebo at day 90 (p<0.001). Practical read: strongest signals are early neurological recovery, aphasia, and hemorrhage protection; durable functional benefit remains uncertain.

IV is standard: 10–30 mL diluted in 100–250 mL saline, infused over 30–60 minutes, in courses of 10–21 days,. Intramuscular use is documented: 10 mL/day for 30 days reduced post-stroke spasticity in outpatients; preterm infants received 0.1 mL/kg IM weekly in an RCT. Oral is not supported: an oral cerebroprotein hydrolysate chart review showed minimal cognitive change in dementia, and GI degradation limits peptide bioavailability (community protocol). Cerebrolysin crosses the blood–brain barrier after parenteral dosing. Verdict: IV for acute/rehab courses; IM workable for maintenance; oral not evidence-based.

Trial-validated regimens (RCT unless noted): acute ischemic stroke + thrombectomy: 30 mL/day IV within 8 h for 21 days, optional second course at days 69–90 (observational); stroke + alteplase: 30 mL/day × 14 days; moderate TBI: 30 mL/day × 10 days (prospective cohort); post-stroke aphasia: 30 mL/day × 10–21 days with speech therapy; MCI/dementia prevention: 20 mL × 20 infusions, repeated yearly for 3 years; ALS pilot: 10 mL/day, 5 days/week month 1, then 3 days/week months 2–3; postoperative cervical myelopathy: 5–10 mL/day × 10–21 days. General pattern: 30 mL combined with multidisciplinary rehabilitation outperforms smaller doses, and short courses or late starts reduce benefit.

Generally, with one rare serious exception. A 12-RCT safety meta-analysis (N=2,202) found no significant difference in serious adverse events versus placebo, with the lowest SAE rate at the 50 mL dose (RR 0.6); typical side effects are mild and transient. Counterpoint: Cochrane review flags possible increase in non-fatal SAEs with 30 mL × 10-day schedule (RR 2.87). A published case of life-threatening intravenous anaphylaxis confirms real allergenic potential (porcine-derived); first-infusion observation is prudent. Cerebrolysin did not increase seizure frequency in epilepsy patients, and in stroke it lowered rather than raised hemorrhagic-transformation risk,. ALS add-on to riluzole was well tolerated.

Versus classic nootropics: a Vietnamese multicenter study (N=398) favored Cerebrolysin over comparator nootropic therapy on mRS, NIHSS, and MoCA; one small trial found no difference between Cerebrolysin, piracetam, and control in moderate stroke. Versus generics: head-to-head assays showed claimed-equivalent peptide preparations had different peptide composition and lacked neurotrophic activity (product identity matters). Oral cerebroprotein hydrolysate shows minimal cognitive effects.

Store unopened ampoules at room temperature, protected from light; ampoules are single-use (community protocol). Administration is IV/injection-based and typically clinic-delivered, so travel requires arranging local infusions (registration and availability differ by country),. Pregnancy and breastfeeding: no human safety data; standard practice is avoidance (community protocol). Pediatric use exists (preterm-infant RCT at 0.1 mL/kg weekly ) but is not a regulatory standard.